Clinical Trials Logo

Filter by:
NCT ID: NCT06001229 Not yet recruiting - Low Back Pain Clinical Trials

The Micheli Functional Scale's Validity and Reliability

Start date: August 18, 2023
Phase:
Study type: Observational

The purpose of this study is to assess the reliability and validity of the "Micheli Functional Scale" in the Turkish context.

NCT ID: NCT06002529 Not yet recruiting - Clinical trials for To Evaluate the Clearance Rate of Uremic Toxin by HFR

Hemodiafiltration With Endogenous Reinfusion on Uremic Toxins Clearance of Maintenance Hemodialysis Patients

Start date: August 18, 2023
Phase: N/A
Study type: Interventional

1.1Primary Objective To evaluate the clearance rate of uremic toxin β2-microglobulin (β2-MG), indoxyl sulfate and λ-free light chain (λFLC) by HFR. 1.2Secondary Objectives 1.1.1 To evaluate the clearance of low molecular weight uremic toxin urea (spKt/V, URR). 1.1.2 To evaluate the clearance of other middle molecules and macromolecular uremic toxins, including α1-microglobulin (α1-MG), κ-free light chain (κFLC), homocysteine (Hcy), interleukin-6 (IL-6), p-cresol, YKL-40, complement factor D (CFD), leptin, hippuric acid, trimethylamine oxide (TMAO), asymmetric dimethylarginine (ADMA), tumor necrosis factor-α (TNF- α), myoglobin, fibroblast growth factor 23 (FGF23) and intact parathyroid hormone (iPTH). 1.1.3 To evaluate the clearance of serum albumin, branched chain amino acids and vitamins A, C, E. 1.1.4 To evaluate the comfort of HFR treatment for MHD patients.

NCT ID: NCT06015243 Not yet recruiting - Clinical trials for Chronic Rhinosinusitis With Nasal Polyps

The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Start date: August 18, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, multicenter, extension study to evaluate the long-term safety and efficacy of GR1802 injection in patients with Chronic Rhinosinusitis With Nasal Polyps

NCT ID: NCT03642496 Not yet recruiting - B-Cell Malignancies Clinical Trials

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

Start date: August 19, 2018
Phase: Early Phase 1
Study type: Interventional

This study is to determine the safety, including potential dose limiting toxicities, and efficiency of ET019002-T cells and the duration of in vivo survival of ET019002-T cells in patients with relapsed/refractory B-Cell Malignancies.

NCT ID: NCT04001699 Not yet recruiting - Multimorbidity Clinical Trials

Interprofessional Preoperative Geriatric Assessment for Older Arthroplasty Patients With Multimorbidity

IPPGA-RCT
Start date: August 19, 2019
Phase: N/A
Study type: Interventional

The objective of this randomized control trial is to investigate effects and cost effectiveness of interprofessional preoperative assessment among older knee or hip arthroplasty patients. The main hypothesis is that preoperative assessment and optimization have a positive impact on the patents' quality of life and expenditure of social and health care services.

NCT ID: NCT05504005 Not yet recruiting - Diabetes Mellitus Clinical Trials

Clinical Validation of mμSORS for Noninvasive Blood Glucose Detection

Start date: August 19, 2022
Phase: N/A
Study type: Interventional

This is a single-center, open-label, prospective study. Blood glucose was measured at different time points during oral glucose tolerance testing in healthy subjects and patients with type 2 diabetes mellitus, using both venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). Venous plasma glucose was set as gold standard.The two measurements were collected synchronously so as to calculate the mean absolute relative difference (MARD) and the consensus error grid (CEG). Accuracy of non-invasive blood glucose testing by mμSORS will be validated. MARD for two measurement methods in different blood glucose ranges and the effect of mμSORS on safety in the patient such as adverse events will also be assessed.

NCT ID: NCT05513105 Not yet recruiting - Clinical trials for Iron Study of Neonates: Factors Affecting and Impact on Their Health Status at Birth in Assuit University Children's Hospital

Iron Study of Neonates Iron Study of Neonates Birth in Assuit University Children's Hospital

Start date: August 19, 2022
Phase:
Study type: Observational

Iron study of neonates: factors affecting and impact on their health status at birth in Assuit University Children's Hospital

NCT ID: NCT06011044 Not yet recruiting - Clinical trials for Intercostal Nerve Block

Intercostal Nerve Block With Local Anesthesia Administered Via Incision-specific Multi-site Injection for Thoracic Surgery

Start date: August 19, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test analgesic effect of intercostal nerve block in different range. The main question it aims to answer are: question 1: whther incision-specific multi-site injection (ISMSI, from the 3rd to 8th intercostal nerve) can improve the analgesic benefits . The participants will be divided into three groups to compare the analgesic effects of different intercostal nerve blocks

NCT ID: NCT05330182 Not yet recruiting - Clinical trials for Clostridioides Difficile Infection

LMN-201 for Prevention of C. Difficile Infection Recurrence

Start date: August 19, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.

NCT ID: NCT06246916 Not yet recruiting - Melanoma Clinical Trials

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

Start date: August 19, 2024
Phase: Phase 3
Study type: Interventional

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children. The study is looking at several other research questions, including: - What side effects may happen from taking the study drugs. - How much study drug is in the blood at different times. - Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)